Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research (Q34147040)

31 July 2017

1 reference

title

Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research (English)

1 reference

31 July 2017

0 references

1 reference

ChEBI release 2020-05-28

John B Murray

1

1 reference

31 July 2017

1 May 2002

1 reference

The Journal of Psychology

31 July 2017

1 reference

31 July 2017

136

1 reference

31 July 2017

3

1 reference

31 July 2017

319-327

1 reference

Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia

31 July 2017

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

The case of frontostriatal dysfunction in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

Evidence of glutamatergic deficiency in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

A comparison of the discriminative stimulus properties of phencyclidine, given intraperitoneally or intraventricularly in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

A new route to treating schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00223980209604159

10.1080/00223980209604159

21 January 2018

Identifiers

DOI

1 reference

release_nt34pw2tu5hdfbduggp7w7gsam

31 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nt34pw2tu5hdfbduggp7w7gsam

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

12206280

1 reference

PubMed ID

12206280